Is DMAC or MAZE more profitable?

Maze Therapeutics' return on equity of -36.62% beat DiaMedica Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets DiaMedica Therapeutics N/A -77.15% -69.23% Maze Therapeutics N/A -36.62% -31.78%

Which has preferable valuation and earnings, AVBP or DMAC?

DiaMedica Therapeutics is trading at a lower price-to-earnings ratio than ArriVent BioPharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio ArriVent BioPharma N/A N/A -$166.31M -$3.47 N/A DiaMedica Therapeutics N/A N/A -$32.77M -$0.71 N/A

Is AVBP or DMAC more profitable?

ArriVent BioPharma's return on equity of -48.98% beat DiaMedica Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets ArriVent BioPharma N/A -48.98% -45.44% DiaMedica Therapeutics N/A -77.15% -69.23%

DiaMedica Therapeutics (DMAC) Competitors

$6.74 -0.08 (-1.17%)

Closing price 07/24/2026 04:00 PM Eastern

Extended Trading

$6.74 0.00 (0.00%)

As of 07/24/2026 07:34 PM Eastern

Compare

DMAC vs. RXRX, MAZE, AVBP, XERS, and SEPN

Should you buy DiaMedica Therapeutics stock or one of its competitors? MarketBeat compares DiaMedica Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with DiaMedica Therapeutics include Recursion Pharmaceuticals (RXRX), Maze Therapeutics (MAZE), ArriVent BioPharma (AVBP), Xeris Biopharma (XERS), and Septerna (SEPN). These companies are all part of the "pharmaceutical products" industry.

How does DiaMedica Therapeutics compare to Recursion Pharmaceuticals?

Recursion Pharmaceuticals (NASDAQ:RXRX) and DiaMedica Therapeutics (NASDAQ:DMAC) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, profitability, analyst recommendations, earnings, dividends, risk and media sentiment.

Recursion Pharmaceuticals presently has a consensus price target of $8.10, suggesting a potential upside of 173.65%. DiaMedica Therapeutics has a consensus price target of $12.00, suggesting a potential upside of 78.04%. Given Recursion Pharmaceuticals' higher probable upside, equities analysts plainly believe Recursion Pharmaceuticals is more favorable than DiaMedica Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Recursion Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20
DiaMedica Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

DiaMedica Therapeutics has lower revenue, but higher earnings than Recursion Pharmaceuticals. DiaMedica Therapeutics is trading at a lower price-to-earnings ratio than Recursion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Recursion Pharmaceuticals	$65.74M	23.86	-$644.76M	-$1.20	N/A
DiaMedica Therapeutics	N/A	N/A	-$32.77M	-$0.71	N/A

89.1% of Recursion Pharmaceuticals shares are held by institutional investors. Comparatively, 10.1% of DiaMedica Therapeutics shares are held by institutional investors. 6.7% of Recursion Pharmaceuticals shares are held by insiders. Comparatively, 5.0% of DiaMedica Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Recursion Pharmaceuticals has a beta of 1, suggesting that its stock price has a similar volatility profile to the broader market.Comparatively, DiaMedica Therapeutics has a beta of 0.97, suggesting that its stock price is 3% less volatile than the broader market.

DiaMedica Therapeutics has a net margin of 0.00% compared to Recursion Pharmaceuticals' net margin of -842.95%. Recursion Pharmaceuticals' return on equity of -54.33% beat DiaMedica Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Recursion Pharmaceuticals	-842.95%	-54.33%	-40.60%
DiaMedica Therapeutics	N/A	-77.15%	-69.23%

In the previous week, Recursion Pharmaceuticals had 2 more articles in the media than DiaMedica Therapeutics. MarketBeat recorded 3 mentions for Recursion Pharmaceuticals and 1 mentions for DiaMedica Therapeutics. DiaMedica Therapeutics' average media sentiment score of 1.87 beat Recursion Pharmaceuticals' score of 0.94 indicating that DiaMedica Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Recursion Pharmaceuticals	Positive
DiaMedica Therapeutics	Very Positive

Summary

Recursion Pharmaceuticals beats DiaMedica Therapeutics on 9 of the 15 factors compared between the two stocks.

How does DiaMedica Therapeutics compare to Maze Therapeutics?

DiaMedica Therapeutics (NASDAQ:DMAC) and Maze Therapeutics (NASDAQ:MAZE) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, analyst recommendations, dividends, institutional ownership, earnings, media sentiment, valuation and profitability.

10.1% of DiaMedica Therapeutics shares are held by institutional investors. 5.0% of DiaMedica Therapeutics shares are held by insiders. Comparatively, 5.3% of Maze Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

DiaMedica Therapeutics presently has a consensus target price of $12.00, indicating a potential upside of 78.04%. Maze Therapeutics has a consensus target price of $66.00, indicating a potential upside of 138.44%. Given Maze Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Maze Therapeutics is more favorable than DiaMedica Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DiaMedica Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
Maze Therapeutics	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	3.00

Maze Therapeutics' return on equity of -36.62% beat DiaMedica Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DiaMedica Therapeutics	N/A	-77.15%	-69.23%
Maze Therapeutics	N/A	-36.62%	-31.78%

In the previous week, Maze Therapeutics had 3 more articles in the media than DiaMedica Therapeutics. MarketBeat recorded 4 mentions for Maze Therapeutics and 1 mentions for DiaMedica Therapeutics. DiaMedica Therapeutics' average media sentiment score of 1.87 beat Maze Therapeutics' score of 1.24 indicating that DiaMedica Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
DiaMedica Therapeutics	Very Positive
Maze Therapeutics	Positive

DiaMedica Therapeutics has a beta of 0.97, indicating that its share price is 3% less volatile than the broader market. Comparatively, Maze Therapeutics has a beta of 2.14, indicating that its share price is 114% more volatile than the broader market.

DiaMedica Therapeutics has higher earnings, but lower revenue than Maze Therapeutics. Maze Therapeutics is trading at a lower price-to-earnings ratio than DiaMedica Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DiaMedica Therapeutics	N/A	N/A	-$32.77M	-$0.71	N/A
Maze Therapeutics	$20M	76.60	-$131.12M	-$2.53	N/A

Summary

Maze Therapeutics beats DiaMedica Therapeutics on 10 of the 15 factors compared between the two stocks.

How does DiaMedica Therapeutics compare to ArriVent BioPharma?

ArriVent BioPharma (NASDAQ:AVBP) and DiaMedica Therapeutics (NASDAQ:DMAC) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, dividends, institutional ownership, valuation, profitability and media sentiment.

ArriVent BioPharma currently has a consensus price target of $44.83, indicating a potential upside of 41.30%. DiaMedica Therapeutics has a consensus price target of $12.00, indicating a potential upside of 78.04%. Given DiaMedica Therapeutics' higher possible upside, analysts clearly believe DiaMedica Therapeutics is more favorable than ArriVent BioPharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ArriVent BioPharma	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78
DiaMedica Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

ArriVent BioPharma's return on equity of -48.98% beat DiaMedica Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ArriVent BioPharma	N/A	-48.98%	-45.44%
DiaMedica Therapeutics	N/A	-77.15%	-69.23%

In the previous week, ArriVent BioPharma had 2 more articles in the media than DiaMedica Therapeutics. MarketBeat recorded 3 mentions for ArriVent BioPharma and 1 mentions for DiaMedica Therapeutics. DiaMedica Therapeutics' average media sentiment score of 1.87 beat ArriVent BioPharma's score of 0.63 indicating that DiaMedica Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
ArriVent BioPharma	Positive
DiaMedica Therapeutics	Very Positive

9.5% of ArriVent BioPharma shares are owned by institutional investors. Comparatively, 10.1% of DiaMedica Therapeutics shares are owned by institutional investors. 8.6% of ArriVent BioPharma shares are owned by insiders. Comparatively, 5.0% of DiaMedica Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

DiaMedica Therapeutics is trading at a lower price-to-earnings ratio than ArriVent BioPharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ArriVent BioPharma	N/A	N/A	-$166.31M	-$3.47	N/A
DiaMedica Therapeutics	N/A	N/A	-$32.77M	-$0.71	N/A

ArriVent BioPharma has a beta of 1.29, meaning that its share price is 29% more volatile than the broader market. Comparatively, DiaMedica Therapeutics has a beta of 0.97, meaning that its share price is 3% less volatile than the broader market.

Summary

ArriVent BioPharma beats DiaMedica Therapeutics on 9 of the 14 factors compared between the two stocks.

How does DiaMedica Therapeutics compare to Xeris Biopharma?

DiaMedica Therapeutics (NASDAQ:DMAC) and Xeris Biopharma (NASDAQ:XERS) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, valuation, institutional ownership, earnings, analyst recommendations, risk, media sentiment and profitability.

Xeris Biopharma has a net margin of 3.81% compared to DiaMedica Therapeutics' net margin of 0.00%. Xeris Biopharma's return on equity of 735.00% beat DiaMedica Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DiaMedica Therapeutics	N/A	-77.15%	-69.23%
Xeris Biopharma	3.81%	735.00%	3.24%

In the previous week, Xeris Biopharma had 2 more articles in the media than DiaMedica Therapeutics. MarketBeat recorded 3 mentions for Xeris Biopharma and 1 mentions for DiaMedica Therapeutics. DiaMedica Therapeutics' average media sentiment score of 1.87 beat Xeris Biopharma's score of 1.64 indicating that DiaMedica Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
DiaMedica Therapeutics	Very Positive
Xeris Biopharma	Very Positive

Xeris Biopharma has higher revenue and earnings than DiaMedica Therapeutics. DiaMedica Therapeutics is trading at a lower price-to-earnings ratio than Xeris Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DiaMedica Therapeutics	N/A	N/A	-$32.77M	-$0.71	N/A
Xeris Biopharma	$291.85M	4.92	$550K	$0.06	138.67

10.1% of DiaMedica Therapeutics shares are owned by institutional investors. Comparatively, 42.8% of Xeris Biopharma shares are owned by institutional investors. 5.0% of DiaMedica Therapeutics shares are owned by insiders. Comparatively, 4.4% of Xeris Biopharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

DiaMedica Therapeutics presently has a consensus target price of $12.00, suggesting a potential upside of 78.04%. Xeris Biopharma has a consensus target price of $10.80, suggesting a potential upside of 29.81%. Given DiaMedica Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe DiaMedica Therapeutics is more favorable than Xeris Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DiaMedica Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
Xeris Biopharma	0 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.57

DiaMedica Therapeutics has a beta of 0.97, suggesting that its share price is 3% less volatile than the broader market. Comparatively, Xeris Biopharma has a beta of 0.62, suggesting that its share price is 38% less volatile than the broader market.

Summary

Xeris Biopharma beats DiaMedica Therapeutics on 9 of the 14 factors compared between the two stocks.

How does DiaMedica Therapeutics compare to Septerna?

DiaMedica Therapeutics (NASDAQ:DMAC) and Septerna (NASDAQ:SEPN) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, risk, profitability, institutional ownership, media sentiment, earnings, dividends and analyst recommendations.

10.1% of DiaMedica Therapeutics shares are owned by institutional investors. 5.0% of DiaMedica Therapeutics shares are owned by company insiders. Comparatively, 5.8% of Septerna shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

DiaMedica Therapeutics has a beta of 0.97, suggesting that its stock price is 3% less volatile than the broader market. Comparatively, Septerna has a beta of 2.29, suggesting that its stock price is 129% more volatile than the broader market.

DiaMedica Therapeutics presently has a consensus price target of $12.00, indicating a potential upside of 78.04%. Septerna has a consensus price target of $45.89, indicating a potential upside of 38.64%. Given DiaMedica Therapeutics' higher probable upside, equities analysts clearly believe DiaMedica Therapeutics is more favorable than Septerna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DiaMedica Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
Septerna	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82

In the previous week, Septerna had 1 more articles in the media than DiaMedica Therapeutics. MarketBeat recorded 2 mentions for Septerna and 1 mentions for DiaMedica Therapeutics. DiaMedica Therapeutics' average media sentiment score of 1.87 beat Septerna's score of 0.88 indicating that DiaMedica Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
DiaMedica Therapeutics	Very Positive
Septerna	Positive

DiaMedica Therapeutics has a net margin of 0.00% compared to Septerna's net margin of -49.88%. Septerna's return on equity of -12.72% beat DiaMedica Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DiaMedica Therapeutics	N/A	-77.15%	-69.23%
Septerna	-49.88%	-12.72%	-8.87%

DiaMedica Therapeutics has higher earnings, but lower revenue than Septerna. Septerna is trading at a lower price-to-earnings ratio than DiaMedica Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DiaMedica Therapeutics	N/A	N/A	-$32.77M	-$0.71	N/A
Septerna	$72.26M	20.65	-$48.88M	-$0.81	N/A

Summary

Septerna beats DiaMedica Therapeutics on 9 of the 16 factors compared between the two stocks.

Get DiaMedica Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DMAC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

DMAC vs. The Competition

Export

Metric	DiaMedica Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$367.48M	$3.67B	$6.87B	$12.26B
Dividend Yield	N/A	2.19%	2.67%	9.79%
P/E Ratio	-9.49	21.48	27.14	23.64
Price / Sales	N/A	170.08	517.08	89.45
Price / Cash	N/A	157.90	50.54	59.64
Price / Book	6.24	7.88	10.28	6.07
Net Income	-$32.77M	$23.86M	$3.60B	$331.99M
7 Day Performance	-7.67%	-3.82%	-1.27%	-0.63%
1 Month Performance	9.59%	-2.61%	-0.37%	-2.00%
1 Year Performance	33.47%	32.79%	18.30%	13.62%

DiaMedica Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
DMAC DiaMedica Therapeutics	1.7056 of 5 stars	$6.74 -1.2%	$12.00 +78.0%	+38.1%	$367.48M	N/A	N/A	20
RXRX Recursion Pharmaceuticals	2.561 of 5 stars	$2.94 -2.6%	$8.10 +175.5%	-52.7%	$1.56B	$65.74M	N/A	400
MAZE Maze Therapeutics	2.1557 of 5 stars	$28.12 +3.5%	$66.00 +134.7%	+68.3%	$1.56B	$20M	N/A	121	News Coverage Positive News
AVBP ArriVent BioPharma	2.1132 of 5 stars	$33.19 +1.3%	$44.83 +35.1%	+47.9%	$1.55B	N/A	N/A	40
XERS Xeris Biopharma	3.7087 of 5 stars	$8.80 +1.3%	$10.80 +22.7%	+60.9%	$1.52B	$291.85M	146.67	290	News Coverage Analyst Upgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:DMAC) was last updated on 7/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

DiaMedica Therapeutics (DMAC) Competitors

DMAC vs. RXRX, MAZE, AVBP, XERS, and SEPN

How does DiaMedica Therapeutics compare to Recursion Pharmaceuticals?

Summary

How does DiaMedica Therapeutics compare to Maze Therapeutics?

Summary

How does DiaMedica Therapeutics compare to ArriVent BioPharma?

Summary

How does DiaMedica Therapeutics compare to Xeris Biopharma?

Summary

How does DiaMedica Therapeutics compare to Septerna?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DMAC vs. The Competition

DiaMedica Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

DiaMedica Therapeutics (DMAC) Competitors

DMAC vs. RXRX, MAZE, AVBP, XERS, and SEPN

How does DiaMedica Therapeutics compare to Recursion Pharmaceuticals?

Do analysts rate RXRX or DMAC?

Which has better valuation and earnings, RXRX or DMAC?

Do insiders and institutionals have more ownership in RXRX or DMAC?

Which has more volatility and risk, RXRX or DMAC?

Is RXRX or DMAC more profitable?

Does the media favor RXRX or DMAC?

Summary

How does DiaMedica Therapeutics compare to Maze Therapeutics?

Do insiders & institutionals believe in DMAC or MAZE?

Do analysts rate DMAC or MAZE?

Is DMAC or MAZE more profitable?

Does the media refer more to DMAC or MAZE?

Which has more volatility & risk, DMAC or MAZE?

Which has better valuation and earnings, DMAC or MAZE?

Summary

How does DiaMedica Therapeutics compare to ArriVent BioPharma?

Do analysts prefer AVBP or DMAC?

Is AVBP or DMAC more profitable?

Does the media prefer AVBP or DMAC?

Do institutionals and insiders have more ownership in AVBP or DMAC?

Which has preferable valuation and earnings, AVBP or DMAC?

Which has more risk & volatility, AVBP or DMAC?

Summary

How does DiaMedica Therapeutics compare to Xeris Biopharma?

Is DMAC or XERS more profitable?

Does the media refer more to DMAC or XERS?

Which has higher valuation & earnings, DMAC or XERS?

Do institutionals & insiders have more ownership in DMAC or XERS?

Do analysts prefer DMAC or XERS?

Which has more volatility & risk, DMAC or XERS?

Summary

How does DiaMedica Therapeutics compare to Septerna?

Do institutionals and insiders believe in DMAC or SEPN?

Which has more volatility & risk, DMAC or SEPN?

Do analysts recommend DMAC or SEPN?

Does the media refer more to DMAC or SEPN?

Is DMAC or SEPN more profitable?

Which has higher earnings and valuation, DMAC or SEPN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DMAC vs. The Competition

DiaMedica Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools